MyDrHank Review

Dr. Hank, LLC operates the consumer platform. The terms say the platform itself does not practice medicine and that a provider-patient relationship forms with the independent clinician who evaluates the patient. Treatment and prescribing remain subject to that clinician's judgment, and a prescription is not guaranteed.

The service is limited to the United States and depends on a clinician licensed where the patient is located. Product pages use different language such as select states or the contiguous United States, but the site does not publish one product-by-state matrix. The assigned practice and clinician are not named before intake.

MyDrHank says prescriptions are filled through partner compounding pharmacies, but the current terms do not name them or assign products and states to a pharmacy. References to an FDA-registered or accredited pharmacy do not mean the compounded drug is FDA approved. The dispensing label remains the patient-specific source for pharmacy and formula information.

The default oral semaglutide product is a daily compounded tablet combining semaglutide with low-dose ondansetron. Its exact totals are $249 for one month, $635 for three months, $1,143 for six months, or $2,057 for twelve months. Those plan-level monthly rates average to Avg. $206/mo.

A separate rapid-dissolve semaglutide tablet variant lists $399, $1,017, $1,831, and $3,297 across the same terms. The visible annual equivalent and embedded monthly-price field do not reconcile with the one-month total. It stays within the oral semaglutide narrative rather than becoming a second therapy card.

Compounded semaglutide injection is offered with either vitamin B12 or glycine. The shared totals of $259, $660, $1,189, and $2,140 produce Avg. $214/mo. Compounded tirzepatide with either additive costs $349, $890, $1,602, and $2,883, producing Avg. $288/mo. Concentration, additive amount, fill volume, and prescribed titration are not public.

The GLP-1 landing page advertises a $99 first month only with a commitment of at least three months. Standard pricing follows. That introductory claim is not mixed into the regular plan averages and is not shown as an affiliate promotion because no issued tracking relationship or offer compatibility has been verified.

FDA says compounded semaglutide and tirzepatide are not FDA approved and do not undergo agency premarket review for safety, effectiveness, or quality. Current agency policy also limits routine copies of commercially available drugs. Adding another ingredient does not automatically remove a preparation from the essentially-a-copy analysis.

NAD+ appears as a nasal spray and a subcutaneous injection. Nasal NAD+ averages Avg. $164/mo from $199, $507, $913, and $1,644 plans. The 1,000 mg injection averages Avg. $186/mo from $225, $574, $1,033, and $1,859 plans. Route-specific cards remain separate because administration and comparison identity differ.

Glutathione also appears as a nasal spray and a subcutaneous injection. Each uses totals of $149, $380, $684, and $1,231 and averages Avg. $123/mo. The injection maps to an existing AllyRx compounded-injection record; the nasal spray does not. The public site does not provide product-level source or lot documents.

The sermorelin injection page describes subcutaneous use at bedtime on five days each week, while embedded product data lists 3 mg/mL and different vial quantities by term. Its $199, $507, $913, and $1,644 totals produce Avg. $164/mo. The clinician's prescription and pharmacy label control the actual dose.

FDA has reported adverse events after compounded injectable NAD+ consistent with endotoxin exposure and advises compounders to use ingredients suitable for sterile compounding. A separate injectable-glutathione alert concerns dietary-supplement-grade ingredient and a specific supplier lot. Neither notice identifies MyDrHank, but both make pharmacy, source, lot, storage, and certificate questions material.

Sexual-health choices include a combined sildenafil and tadalafil rapid-dissolve product, sildenafil tablets, tadalafil as needed, and tadalafil daily. Their compact displays are Avg. $51/mo, Avg. $30/mo, Avg. $37/mo, and Avg. $41/mo. The combined product remains outside single-drug comparisons.

The public sexual-health pages do not consistently provide strength or tablet quantity before intake. Sildenafil and tadalafil labels contraindicate use with nitrates and riociguat. A patient should disclose cardiovascular history and every prescription, over-the-counter drug, and supplement to the clinician.

Oral minoxidil costs $49, $125, $212, or $361 and averages Avg. $39/mo. Oral finasteride costs $55, $140, $252, or $454 and averages Avg. $45/mo. Strength and quantity are not clearly posted for these individual products.

Oral minoxidil tablets are FDA approved for severe hypertension, not hair loss, and the label contains a boxed warning about serious cardiac effects. Hair-loss prescribing is therefore off label. Finasteride 1 mg is approved for male-pattern hair loss in men, with pregnancy-handling, prostate-specific-antigen, and sexual-adverse-effect precautions in the label.

Five custom hair formulas are consolidated into one editorial card: a minoxidil, finasteride, and biotin tablet; a minoxidil, finasteride, and retinoic-acid topical; a minoxidil, tretinoin, fluocinolone, and finasteride spray; a women's minoxidil, tretinoin, fluocinolone, biotin, and melatonin topical; and a women's minoxidil, vitamin E, and biotin capsule.

Those custom formulas range from Avg. $45/mo to Avg. $62/mo by exact formula. They are not blended into one comparison price because routes and active ingredients differ. FDA has warned that compounded topical finasteride has no approved counterpart, may be systemically absorbed, and can pose transfer risk to others.

Product pages say consultation and delivery are free, insurance is not billed for the GLP-1 program, and HSA or FSA payment may be accepted. Eligibility and reimbursement depend on the expense and plan administrator. The site does not publish a complete insurance policy for every vertical.

The home page says there is no commitment and several landing pages say cancel anytime. The current terms and privacy pages do not provide a complete subscription-renewal, cancellation-deadline, refund, chargeback, or medication-return policy. Long-term prices require substantial prepayment, so the exact checkout agreement should be saved before purchase.

The main site says a clinician writes a prescription within forty-eight hours, while a GLP-1 page describes review within twenty-four hours. The legal terms correctly preserve clinician discretion and do not guarantee a prescription. These time statements should be read as workflow marketing, not a clinical or fulfillment guarantee.

The refill page lists support@mydrhank.com and (888) 588-8094 for refills, subscription changes, and questions, with a typical one-business-day response. It does not publish operating hours, an urgent-clinical pathway, a pharmacy-specific escalation route, or a universal shipping and replacement timeline.

Current terms warn that medication is not shipped in child-resistant packaging. Patients should follow the pharmacy label and storage instructions and keep all medication, syringes, and supplies secured from children and others for whom they were not prescribed.

The privacy policy describes collection of health, prescription, device, cookie, location, and online-activity data, with disclosure to clinicians, pharmacies, service providers, affiliates, advertisers, and analytics providers. It also says the service does not respond to Do Not Track because it does not track customers across third-party sites, which conflicts with an earlier cross-site-activity statement.